It's not clear whether the anti-influenza drug Tamiflu prevents infection or reduces complications, a new analysis suggests.

Researchers combed through more than 16,000 pages of clinical trial data and documents used by regulators to approve oseltamivir, sold as Tamiflu.

Read the complete article here.